About: Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates
Creator	Li, Min Wang, Qi Gao, Guang Jin, Xia Gao, George Chen, Yuxin Zhao, Gan Chen, J Chen, Y Gao, G Hu, Y Li, M Sun, H Sun, S Wang, Q Zhao, R Cheng, Xin Gao, W Sun, Y Zhao, G Su, J Chen, Jianxin Cheng, X Chen, Jinggong Fang, Feng Gao, Wen Gong, Sitao He, Ailiang Hu, Yalin Le Sun, Li, Maohua Ren, Wenlin Su, Junchi Sun, Hunter Sun, Le Sun, Sean Sun, Yufei Xia, Chenxi Zhao, Rongqing Gong, S Fang, F He, A Jin, X Ren, W Xia, C
Source	Elsevier; Medline; PMC
abstract	Abstract The COVID-19 outbreak has become a global pandemic responsible for over 2,000,000 confirmed cases and over 126,000 deaths worldwide. In this study, we examined the immunogenicity of CHO-expressed recombinant SARS-CoV-2 S1-Fc fusion protein in mice, rabbits, and monkeys as a potential candidate for a COVID-19 vaccine. We demonstrate that the S1-Fc fusion protein is extremely immunogenic, as evidenced by strong antibody titers observed by day 7. Strong virus neutralizing activity was observed on day 14 in rabbits immunized with the S1-Fc fusion protein using a pseudovirus neutralization assay. Most importantly, in less than 20 days and three injections of the S1-Fc fusion protein, two monkeys developed higher virus neutralizing titers than a recovered COVID-19 patient in a live SARS-CoV-2 infection assay. Our data strongly suggests that the CHO-expressed SARS-CoV-2 S1-Fc recombinant protein could be a strong candidate for vaccine development against COVID-19.
has issue date	2020-06-24(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2020.06.066
bibo:pmid	32651113
has license	els-covid
sha1sum (hex)	8dae58adf40767d8c09499553a47ca339144b941
schema:url	https://doi.org/10.1016/j.vaccine.2020.06.066
resource representing a document's title	Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates
has PubMed Central identifier	PMC7311893
has PubMed identifier	32651113
schema:publication	Vaccine
resource representing a document's body	covid:8dae58adf40767d8c09499553a47ca339144b941#body_text
is schema:about of	named entity 'vaccine' named entity 'global' named entity 'developed' named entity 'titers' named entity 'OUR' named entity 'USING' named entity 'PSEUDOVIRUS' named entity 'ANTIBODY TITERS' named entity 'RECOMBINANT PROTEIN' named entity 'GLOBAL' named entity 'EXTREMELY' named entity 'FUSION PROTEIN' covid:arg/8dae58adf40767d8c09499553a47ca339144b941 named entity 'candidate' named entity 'rabbits' named entity 'recovered' named entity 'SARS-CoV-2' named entity 'titers' named entity 'day' named entity 'virus' named entity 'antibody' named entity 'virus' named entity 'pseudovirus' named entity 'virus' named entity 'CHO' named entity 'fusion protein' named entity 'assay' named entity 'COVID-19 vaccine' named entity 'infection' named entity 'antibodies' named entity 'microdose' named entity 'plasma' named entity 'SARS-CoV-2' named entity 'antibodies' named entity 'macaques' named entity 'human trials' named entity 'China'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software